Experimental and clinical studies on fluoroquinolone-insusceptible Escherichia coli isolated from patients with urinary tract infections from 1994 to 2007

Acta Medica Okayama

Volumn 63, Issue 5, 2009, Pages 263-272

  Wada, Koichiro ^a   Kariyama, Reiko ^a   Mitsuhata, Ritsuko ^a   Uehara, Shinya ^a   Watanabe, Toyohiko ^a   Monden, Koichi ^a,b   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Araki Urology Clinic   (Japan)

Author keywords

Biofilm; Escherichia coli; Fluoroquinolone; MICs; QRDRs

Indexed keywords

ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BIOFILM; CHILD; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GENETICS; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MUTATION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BIOFILMS; CHILD; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; MUTATION; URINARY TRACT INFECTIONS; YOUNG ADULT;

ESCHERICHIA COLI;

EID: 74349110805     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Eom JS, Hwang BY, Sohn JW, Kim WJ, Kim MJ, Park SC and Cheong HJ: Clinical and molecular epidemiology of quinolone-insusceptible Escherichia coli isolated from urinary tract infection. Microb Drug Resist (2002) 8: 227-234.
2. Kahlmeter G: Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents (2003) Suppl 2: 49-52.
3. The WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme: Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2004. Commun Dis Intell (2006) 30: 129-132.
4. Japanese Journal of Sexual Transmitted Diseases: Diagnosis and treatment guidelines 2008. Nippon Seikansenshou Gakkaishi (Jpn J STD) (2008) 19: Suppl (in Japanese).
5. Hooper DC: Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis (2001) 7: 337-341.
6. Hopkins KL, Davies RH and EJ Threlfall EJ: Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents (2005) 25: 358-373.
7. Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition Document M7-A7. Clinical and Laboratory Standards Institute, Wayne (2006).
8. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement M100-S17. Clinical and Laboratory Standards Institute, Wayne (2007) pp 97-139.
9. Minuth JN, Musher DM and Thorsteinsson SB: Inhibition of the antibacterial activity of gentamicin by urine. J Infect Dis (1976) 133: 14-21.
10. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P and Nachamkin I: Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis (2001) 7: 24-34.
11. Ginsburg AS, Grosset JH and Bishai WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3: 432-442.
12. Hooper DC and Wolfson JS: Mechanisms of fluoroquinolone action and bacterial killing. In Quinolone Antimicrobial Agents, 2nd Ed. Hooper DC, Wolfson JS eds, American Society for Microbiology, Washington DC (1993) pp 53-75.
13. Wang JC: DNA topoisomerases. Annu Rev Biochem (1996) 65: 635-692.
14. Adams DE, Shekhtman EM, Zechiedrich EL, Schmid MB and Cozzarelli NR: The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell (1992) 71: 277-288.
15. Heisig P: Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (1996) 40: 879-885.
16. Bagel S, Hüllen V, Wiedemann B and Heisig P: Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother (1999) 43: 868-875.
17. Komp Lindgren P, Karlsson A and Hughes D: Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother (2003) 47: 3222-3232.
18. Fralick JA: Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol (1996) 178: 5803-5805.
19. Okusu H, Ma D and Nikaido H: AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol (1996) 178: 306-308.
20. Alekshun MN and Levy SB: Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob Agents Chemother (1997) 41: 2067-2075.
21. Robicsek A, Jacoby GA and Hooper DC: The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis (2006) 6: 629-640.
22. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, Shibayama K, Konda T and Arakawa Y: New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother (2007) 51: 3354-3360.
23. Wang A, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, Ding H, Deng Q, Zhang H, Wang C, Liu L, Xu X, Wang L and Shen X: Presence of qnr gene in Escherichia coli and Klebsiella pneumoniae insusceptible to ciprofloxacin isolated from pediatric patients in China. BMC Infect Dis (2008) 8: 68.
24. Onodera Y, Okuda J, Tanaka M and Sato K: Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis. Antimicrob Agents Chemother (2002) 46: 1800-1804.
25. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H and Tanaka M: Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother (1995) 39: 170-174.
26. Kumon H: Management of biofilm infection in the urinary tract. World J Surg (2000) 24: 1193-1196.